Psilocybin clinical trials: what the research shows so far

Psilocybin clinical trials show that the drug, given with psychological support in a controlled clinical setting, can cut depression scores quickly, sometimes within days. The best data also show clear limits: effects can fade within weeks, side effects are common, and the largest trials are still small by drug-approval standards. Psilocybin remains a Schedule I substance under federal law and is not FDA-approved for any condition.

That is the short version. The longer one matters if you are a founder who has heard three different people at three different dinners describe a mushroom retreat as the thing that finally fixed them.

Why founders keep asking about psilocybin

The pattern is familiar. Someone you respect exits, disappears for a few months, and comes back calmer. They mention a guided psilocybin session in Oregon or a retreat abroad. A board member forwards a podcast. By the time the topic reaches you, it arrives packaged as a performance tool, a cure for burnout and a spiritual reset all at once.

The research is more interesting, and more careful, than that story. Psilocybin is being studied as a treatment for specific clinical conditions (depression above all, plus alcohol use disorder and distress at the end of life), in trials with screening, preparation, monitored sessions and follow-up. None of that resembles taking something at a friend's house the weekend after a hard board meeting.

If you are trying to work out whether the hype has any substance, the useful questions are narrow ones. What was measured, in whom, against what control, and for how long did it last?

What the largest psilocybin clinical trials found

The biggest single study to date was published in the New England Journal of Medicine in November 2022. It enrolled 233 participants with treatment-resistant depression at 22 sites across 10 countries in Europe and North America, run by the drug developer Compass Pathways. Participants were randomized to one of three doses of a synthetic psilocybin, with the lowest dose acting as the control. Everyone received psychological support around the session.

The primary result: people who got the highest dose had a larger drop in depression scores at three weeks than people who got the control dose. The middle dose did not separate from control in a statistically meaningful way.

Read the chart carefully. The control group improved too, by 5.4 points, which is what you would expect from a trial where everyone gets preparation, attention and a supportive session. The difference that counts is the gap between the highest dose and the control: 6.6 points on the MADRS scale, which was statistically significant, while the middle dose's 2.5 point gap was not.

Then there is durability. The authors reported that the response "was not sustained at 12 weeks." Anthony Cleare of King's College London put it plainly: "The effects did start to wear off by three months, and we need to know how best to prevent the depression returning."

For a founder, translate that into operating terms. A single intervention produced a real, measurable change in a hard-to-treat group, and the change did not hold on its own. That is a promising signal and an unfinished product.

The smaller studies with longer follow-up

The more optimistic headlines usually trace back to smaller studies. Johns Hopkins researchers followed 27 adults with major depression who received two psilocybin sessions about two weeks apart, alongside extensive preparation with two facilitators; 24 completed the study. At 12 months, 75% met the criteria for response and 58% were in remission, and average depression scores fell from 22.8 before treatment to 7.7 at a year.

Those are striking numbers. They also come from 24 people in a small, early-phase study, most of them white women with an average age of 40. That is the right design for an early study and the wrong basis for a confident conclusion.

What the evidence says, and what it doesn't

Here is where the research stands, sorted by quality rather than by excitement.

Reasonably supported: In randomized trials, psilocybin with psychological support reduced depression symptoms faster and further than a control condition over the short term. NCCIH summarizes trials in which a single psilocybin-assisted session "rapidly reduced symptoms of depression within 8 days, with benefits lasting for 6 weeks," and others where effects lasted up to 5 weeks. The FDA took the early data seriously enough to grant breakthrough therapy designation for treatment-resistant depression in 2018 and for major depressive disorder in 2019.

Promising but early: In alcohol use disorder, NCCIH notes that participants given psilocybin-assisted psychotherapy had fewer heavy drinking days over 32 weeks. For people facing serious illness, psilocybin with psychotherapy "may be safe and effective" for anxiety, depression and existential distress. These are small trials.

Open questions: How long benefits last, and whether they need repeat sessions. How much of the effect comes from the drug versus the preparation, the setting and the therapist. Blinding is a real problem: most people can tell whether they got a high dose, and in the NEJM trial an outside expert noted that participants were not asked to guess which arm they were in. Trial populations are also carefully screened, so results may not apply to people with more complicated medical or psychiatric histories.

Not supported: Claims that psilocybin improves performance, focus or leadership in healthy people. The major trials studied illness, not optimization. There is also no good trial evidence behind microdosing for productivity, and NCCIH lists insomnia, increased anxiety and depression, poor mood and low energy among its reported downsides.

What are the risks of psilocybin?

Side effects in trials were common, even in controlled settings. In the NEJM study, 84% of the highest-dose group reported adverse effects over 12 weeks, most often headache, nausea and dizziness, compared with 75% in the middle-dose group and 72% in the control group. The researchers also reported that "suicidal ideation and intentional self-injury were seen in all dose groups," which is a sober reminder that this was a very ill population and that close follow-up matters.

NCCIH's broader list of adverse effects includes increased blood pressure and heart rate, headache, nausea, fatigue, poor sleep, anxiety, paranoia, hallucinations and, rarely, persistent psychosis. Its contraindications are specific: psilocybin "is not safe for people with psychotic conditions like schizophrenia, schizoaffective disorder, or severe forms of bipolar disorder and borderline personality disorder."

There is a practical risk that the trials do not capture well. Outside a clinic, you have no screening, no reliable product, no medical monitoring and no plan for the days after. If you are considering psilocybin in any form, including a state-licensed program, talk with a physician first, especially if you take psychiatric medication, have a personal or family history of psychosis or bipolar disorder, or have heart disease or high blood pressure.

Is psilocybin legal? Federal law, Oregon and Colorado

Federally, the answer is simple. NCCIH states that psilocybin is "a Schedule 1 controlled substance and possessing it is illegal at the Federal level." Clinical research happens under federal oversight in controlled settings, with approved protocols and trained staff. Breakthrough designation is not approval, and as of this writing no psilocybin medicine has been approved by the FDA.

At the state level, two programs exist. Oregon was the first state to create a regulated psilocybin program. Colorado voters approved Proposition 122 in 2022, making it the second, with licensed facilitators running sessions that last five hours or longer. In Colorado, the Department of Revenue oversees the businesses (healing centers, cultivation, manufacturing, testing) and the Department of Regulatory Agencies licenses facilitators, who must be at least 21 and complete state-approved training.

Two things are worth holding at once. State programs are regulated, which is safer than an unregulated source. They are also not clinical trials: a licensed facilitator is not the same as a psychiatric team, and state participation does not change federal law. Some cities and states have separately decriminalized or deprioritized possession, which again leaves federal law untouched.

What a founder can do this week

None of this is a recommendation to seek out psilocybin. It is a way to think clearly about a topic that will keep coming up.

Name the actual problem. If what you are feeling is persistent low mood, loss of interest, hopelessness or trouble functioning, that is a clinical question, and the fastest route to real help is a physician or psychiatrist. Evidence-based treatments for depression exist today and are legal today.

Read past the headline. When someone sends you a study, ask four questions. How many people? Compared with what? Measured when? Who funded it? The NEJM trial is a useful template: large for the field, industry-run, positive at three weeks, faded by twelve.

Separate the drug from the setting. Much of what trial participants credit to the experience (preparation, a trusted guide, a protected day with no phone, a structured conversation afterward about what came up) is not unique to psilocybin. You can build some of those conditions into your life without breaking any law.

Watch the post-exit window. The months after a liquidity event are when many founders go looking for something that will make sense of the quiet. If that is you, our piece on the identity gap after an exit is a better starting point than a retreat brochure.

Get a baseline on your nervous system. Before chasing an altered state, notice your ordinary one. How fast do you come down after a hard call? How do you sleep after an investor update? A simple daily practice will tell you more about your baseline than any single experience, and it is the foundation for meditation for anxiety when the stakes never drop.

Where meditation fits alongside the research

One consistent thread in the trials is that the session itself is only part of the protocol. Participants are prepared beforehand and supported afterward, because an intense experience is only as useful as a person's capacity to make sense of it and carry it into ordinary life.

That capacity is trainable. Meditation will not replicate a psychedelic experience and is not a treatment for depression. What it does build is the ability to stay present with difficult material, to notice activation in the body before it runs the show, and to return to a steady baseline. That is useful whether or not you ever go near a clinical trial. We write more about practice beyond stress relief in exploring the inner cosmos.

At Cinder, this is the work: private 1:1 coaching for founders and executives that trains stress regulation and steadier attention as skills, and helps people integrate whatever they are going through, from a hard year to the quiet after an exit, into how they actually live and lead.

Building a steadier baseline first

The research on psilocybin is worth following closely, and it is moving. It is also early, narrow and bound up with clinical settings that do not exist at a dinner party or a weekend retreat. The most reliable change most founders can make starts with something less dramatic: a nervous system that can settle on its own, day after day.

Apply for private coaching

Sources

• Psilocybin for Mental Health and Addiction: What You Need To Know, National Center for Complementary and Integrative Health (NIH), 2024
• Largest trial to date shows that psilocybin reduces depression symptoms, King's College London (New England Journal of Medicine study), 2022
• Psilocybin may be effective for treatment-resistant depression, The Pharmaceutical Journal, 2022
• Psilocybin treatment for major depression effective for up to a year for most patients, study shows, Johns Hopkins Medicine, 2022
• Colorado can now issue licenses to psychedelic mushroom therapy facilitators, Stateline, 2025